Gene · 7846
TUBA1A: tubulin alpha 1a
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. TUBA1A: tubulin alpha 1a. Genes, record 7846. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/7846
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q71U36 | Tubulin alpha-1A chain | 451 | 15 | Ensembl, GeneID, HGNC |
Source UniProt
Patents66
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 68520 | Q71U36 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 68521 | Q71U36 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 16026 | Q71U36 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 4045 | Q71U36 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 4045 | Q71U36 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 16026 | Q71U36 | Espacenet |
| US 11934929 B2 | 2024-03-19 | 2 | Q71U36 | Espacenet |
| JP 2023073278 A | 2023-05-25 | 1 | Q71U36 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 93538 | Q71U36 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 93539 | Q71U36 | Espacenet |
1 to 10 of 66
See all 66 patentsDrugs90
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AGS-16C3F | CHEMBL4594455 | Tubulin disrupting agent | DISRUPTING AGENT | ChEMBL |
| ANETUMAB RAVTANSINE | CHEMBL2109629 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ANG1005 | CHEMBL1089636 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ANVATABART OPADOTIN | CHEMBL4297892 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| APRUTUMAB IXADOTIN | CHEMBL4650293 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ASG-5ME | CHEMBL2109574 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| AVE-9633 | CHEMBL2109266 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| AZINTUXIZUMAB VEDOTIN | CHEMBL4297859 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| BELANTAMAB MAFODOTIN | CHEMBL4298209 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| BIIB-015 | CHEMBL2109575 | Tubulin inhibitor | INHIBITOR | ChEMBL |
1 to 10 of 90
See all 90 drugsTrials8,728
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07604766 | PACLITAXEL | PHASE3 | ClinicalTrials.gov | |
| NCT07602907 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07601737 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07601178 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07599163 | PACLITAXEL | ClinicalTrials.gov | ||
| NCT07595770 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07594548 | PACLITAXEL | PHASE1 | ClinicalTrials.gov | |
| NCT07591467 | DOCETAXEL | PHASE3 | ClinicalTrials.gov | |
| NCT07589972 | VINORELBINE | ClinicalTrials.gov | ||
| NCT07588698 | VINCRISTINE SULFATE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 8,728
See all 8,728 trialsNIH grants1,314
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | TUBA1A papers | Newest fiscal year |
|---|---|---|---|
| R01NS058721 | ACC: Callosal Agenesis as a Window into Common Neurodevelopmental Disorders | 11 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 4 | 2025 |
| R01GM094231 | COMPUTATIONAL TOOLS FOR MASS SPECTROMETRY-BASED INTERACTOME DATA | 4 | 2025 |
| T32GM136444 | Predoctoral Training in Molecular and Cellular Biology | 4 | 2025 |
| P30CA036727 | Buffett Cancer Center Support Grant | 3 | 2025 |
| P30CA054174 | Mays Cancer Center at UT Health SA | 3 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 3 | 2025 |
| R35GM119569 | Deciphering Post-transcriptional Gene Regulatory Networks During Periods of Host-Pathogen Interaction and Innate Immune Activation | 3 | 2025 |
| R37NS035129 | Human Epilepsy Genetics - Mosaic Mutations in Focal Epilepsy | 3 | 2025 |
| P20GM103436 | IDeA Networks of Biomedical Research Excellence in Kentucky | 2 | 2025 |
1 to 10 of 1,314Source NIH's project files
See all 1,314 nih grantsPapers1,672
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Proteomics reveal serum biomarkers for early diagnosis in premature ovarian insufficiency. | Front Endocrinol (Lausanne) | 2026 | 42824073 | PubTator, text mining | PubMed |
| Diagnostic Yield of Sequencing in Prenatal Agenesis of the Corpus Callosum in a Well-Phenotyped International Cohort. | Prenat Diagn | 2026 | 42791457 | PubTator, text mining | PubMed |
| The effect and mechanism of TIPE in promoting M2 polarization through DcR3 in the microenvironment of colorectal cancer. | Cancer Immunol Immunother | 2026 | 42776288 | PubTator, text mining | PubMed |
| Gain-of-function suppressors restore microtubule dynamics and rescue dominant-negative tubulinopathies. | Nat Cell Biol | 2026 | 42728306 | PubTator, text mining | PubMed |
| Integrative single-cell and bulk transcriptomic profiling identify peripheral T-cell-associated candidate biomarkers in community-acquired pneumonia. | Int J Med Sci | 2026 | 42694836 | PubTator, text mining | PubMed |
| Developmental Profiles Associated with TUBA1A, TUBB2A, TUBB2B, and TUBB3 Tubulinopathy Conditions. | Am J Intellect Dev Disabil | 2026 | 42593952 | PubTator, text mining | PubMed |
| Genotypic and phenotypic heterogeneity in tubulinopathies: insights from a Turkish multicenter cohort. | Neurol Sci | 2026 | 42472988 | PubTator, text mining | PubMed |
| Alterations in the protein lactylation landscape of sperm from patients with varicocele-associated asthenozoospermia. | Front Endocrinol (Lausanne) | 2026 | 42416903 | PubTator, text mining | PubMed |
| Integrative Bioinformatic Characterization of the HDAC6-Driven Cytoskeleton-Wnt Signaling Interface in Hepatocellular Carcinoma: Implications for Immune Modulation and Therapeutic Targeting. | Int J Mol Sci | 2026 | 42352927 | PubTator, text mining | PubMed |
| Genetic causes of the lissencephaly spectrum: insights from chromosomal microarray and clinical/whole-exome sequencing. | Croat Med J | 2026 | 42286901 | PubTator, text mining | PubMed |
1 to 10 of 1,672
See all 1,672 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/7846
GET https://conductscience.org/api/genes/v1/7846/patents?page=2